Targeting Ikaros and Aiolos: Reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide
Y Liu, CC Mo, MA Hartley-Brown… - Expert Review of …, 2024 - Taylor & Francis
Introduction The treatment of multiple myeloma (MM) is evolving rapidly. Quadruplet
regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 …
regimens incorporating proteasome inhibitors, immunomodulatory drugs (IMiDs), and CD38 …
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the …
CC Mo, E Richardson, E Calabretta, F Corrado… - Blood Reviews, 2024 - Elsevier
Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …
Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma
For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation
antigen (BCMA)–directed chimeric antigen receptor T-cell therapy (CAR-T), optimal salvage …
antigen (BCMA)–directed chimeric antigen receptor T-cell therapy (CAR-T), optimal salvage …
N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair
S Jiang, L Gao, J Li, F Zhang, Y Zhang… - Frontiers in Cell and …, 2024 - frontiersin.org
Studies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by
the abnormalities of various molecules and microenvironments. Exploring these resistance …
the abnormalities of various molecules and microenvironments. Exploring these resistance …
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
J Lind, O Aksoy, M Prchal-Murphy, F Fan… - Blood Cancer …, 2024 - nature.com
Deregulation of transcription factors (TFs) leading to uncontrolled proliferation of tumor cells
within the microenvironment represents a hallmark of cancer. However, the biological and …
within the microenvironment represents a hallmark of cancer. However, the biological and …
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Despite significant improvement in the outcomes of patients with newly diagnosed multiple
myeloma (NDMM) with novel therapies, there is still an underserved high-risk (HR) …
myeloma (NDMM) with novel therapies, there is still an underserved high-risk (HR) …
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
E Barbieri, EA Martino, E Rivolti… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Gain/amplification of 1q (+ 1q) represents one of the most prevalent cytogenetic
abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the …
abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the …
[HTML][HTML] First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell …
Simple Summary Daratumumab (DARA) plus bortezomib, thalidomide, and dexamethasone
(D-VTd) represent the standard of induction care in Europe for autologous stem cell …
(D-VTd) represent the standard of induction care in Europe for autologous stem cell …
Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study
Y Zhang, C Shan, X Zhang, Y Liu, Y Xia… - Frontiers in …, 2024 - frontiersin.org
Introduction Multiple myeloma (MM) is a leading cause of hematopoietic cancer-related
mortality, accounting for 20% of deaths. MM-targeted therapies have demonstrated efficacy …
mortality, accounting for 20% of deaths. MM-targeted therapies have demonstrated efficacy …
[HTML][HTML] Development and Validation of an Improved HPLC-MS/MS Method for Quantifying Total and Unbound Lenalidomide in Human Plasma
S Lee, S Yang, WS Shim, E Song, S Han, SS Park… - Pharmaceutics, 2024 - mdpi.com
Background/Objectives: This study aimed to develop a fully validated HPLC-MS/MS method
for quantifying total and unbound lenalidomide concentrations in human plasma. Methods …
for quantifying total and unbound lenalidomide concentrations in human plasma. Methods …